Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
NOX2 Inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "NOX2 Inhibitor" in MCE Product Catalog:
78
78 Publications Verification
Cat. No.: HY-18950
CAS No.: 1415925-18-6
Research Areas:
GSK2795039 is a NADPH oxidase 2 (NOX2) inhibitor with a mean pIC50 of 6 in different cell-free assays. GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption .
GSK2795039 reduces apoptosis .
5
5 Cited Publications
Cat. No.: HY-N2255
CAS No.: 25127-29-1
2
Target:
Research Areas:
APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 effectively prevents kidney injury .
2
2 Cited Publications
Synonyms: Ewha-18278 free base; Isuzinaxib free base
Target:
Research Areas:
APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury .
1
1 Cited Publications
Cat. No.: HY-P5381
CAS No.: 329902-61-6
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
1
1 Cited Publications
Research Areas:
Phox-I2 is a selective inhibitor of p67 phox-Rac1 interaction, binds to p67 phox with high affinity with a Kd of ~150 nM. Phox-I2 is a NADPH oxidase 2 (NOX2) inhibitor and inhibits reactive oxygen species (ROS) production .
Cat. No.: HY-173591
CAS No.: 2785323-68-2
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
T0080 is a central nervous system-penetrant FPR1 inhibitor. By functionally blocking the FPR1 signaling pathway, T0080 effectively reduces neutrophil infiltration into ischemic brain tissue and maintains the integrity of the blood-brain barrier. T0080 alleviates tPA-associated hemorrhagic transformation, inhibits demyelination responses and the expression of NOX2. T0080 also possesses anti-apoptotic (apoptosis) and anti-inflammatory properties, thereby protecting myelin and reducing neurological deficits. T0080 is widely used in studies related to ischemic stroke complicated by hemorrhagic transformation after tPA thrombolysis, as well as multiple sclerosis .
Target:
Research Areas:
NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy .
Research Areas:
MJ-33 lithium salt is a competitive phospholipase A2 (PLA2) inhibitor with an IC50 of 0.3 μM. MJ-33 lithium salt inhibits NOX2 activation and reduces ROS production by blocking the PLA2 activity of Prdx6. MJ-33 lithium salt effectively inhibits the activity of acidic PLA2 (pH 4.0) and reduces the degradation of alveolar surfactant phosphatidylcholine (PC), but exerts no effect on alkaline PLA2 (pH 8.5). MJ-33 lithium salt significantly alleviates lung oxidative injury induced by ischemia-reperfusion (I/R). MJ-33 lithium salt significantly inhibits the invasion, migration and adhesion abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 lithium salt can be used for the research of ROS-related diseases and prostate cancer .
Target:
Research Areas:
GLX481304 is a specific inhibitor of Nox-2 and -4, with IC50s of 1.25 μM. GLX481304 suppresses ROS production in isolated mouse cardiomyocytes and improves cardiomyocyte contractility. GLX481304 can be used for research of ischemic injury to the heart .
Target:
Research Areas:
NOX2-IN-2 diTFA (compound 33) is a potent NOX2 inhibitor targeting the p47phox-p22phox protein-protein interaction with a Ki of 0.24 μM. NOX2-IN-2 diTFA inhibits ROS production derived from NOX2 in cells .
Cat. No.: HY-W509797
CAS No.: 21618-92-8
Target:
Drug Metabolite TNF Receptor IKK NF-κB Autophagy NOD-like Receptor (NLR) NADPH Oxidase Keap1-Nrf2
Research Areas:
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone is an intestinal microbiota metabolite of (-)-Epicatechin (HY-N0001). 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone downregulates TNF-α-stimulated phosphorylation of IKK and IκBα, inhibits the transcriptional activation of NF-κB, and suppresses the expression of adhesion molecules and chemokines. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone promotes autophagy, alleviates oxidative stress, maintains osteoblast differentiation, induces G1 phase arrest, inhibits adipogenesis, and scavenges ABTS free radicals. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone inhibits the adhesion of uropathogenic Escherichia coli to bladder epithelial cells; when used in combination with Curcumin (HY-N0005), it downregulates the NLRP3 and NOX2/Nrf2 signaling pathways, thereby reducing microglial activation. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone can be used in research related to diabetes, atherosclerosis, osteoporosis, obesity, neurodegenerative diseases involving microglial activation, and urinary tract infections .
Cat. No.: HY-156425
CAS No.: 2648709-79-7
Target:
Research Areas:
NOX2-IN-2 (compound 33) is a potent NOX2 inhibitor targeting the p47phox-p22phox protein-protein interaction with a Ki of 0.24 μM. NOX2-IN-2 inhibits ROS production derived from NOX2 in cells .
Cat. No.: HY-156424
CAS No.: 2648709-25-3
Target:
Research Areas:
NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2). NOX2-IN-1 targets the p47phox p22phox protein protein interaction with favorable binding affinities and cellular activities .
Cat. No.: HY-173096
Target:
Research Areas:
NCATS-SM7270 is a highly specific NOX2 inhibitor, with an IC50 of 4.09 μM. NCATS-SM7270 protects mice from mild traumatic brain injury .
Cat. No.: HY-172451
Target:
NADPH Oxidase Monoamine Oxidase Reactive Oxygen Species (ROS) NO Synthase Interleukin Related
Research Areas:
MC4762 is an inhibitor of NOX2 and MAOB, with IC50 values of 0.155 μM and 0.182 μM, respectively. MC4762 has anti-inflammatory activity, can inhibit the production of ROS, and downregulate the expression of pro-inflammatory cytokines iNOS, IL-1β, and IL-6 .
Cat. No.: HY-148936
CAS No.: 1990478-58-4
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GLX481372 is a NADPH Oxidase (NOX) inhibitor. GLX481372 potently inhibits NOX4/5 activities with IC50 values of 0.68 and 0.57 μM. GLX481372 also has weak inhibitory activity against NOX1, NOX2, and NOX3, with IC50 values of 7, 16 and 3.2 μM respectively. GLX481372 can inhibit ROS production. GLX481372 can be used for the researches of inflammation, cardiovascular and metabolic disease, such as diabetes .
Cat. No.: HY-160524
CAS No.: 921145-98-4
Target:
Research Areas:
NOX2-IN-3 (compound 3) is an inhibitor of NOX2 (NADPH Oxidase 2). NOX2-IN-3 sensitizes tumor cells to MRTX1133 (HY-134813) .
Cat. No.: HY-136271
CAS No.: 137300-78-8
Research Areas:
MJ-33 is a competitive phospholipase A₂ (PLA₂) inhibitor with an IC50 of 0.3 μM. MJ-33 inhibits the activation of NOX2 by blocking the PLA₂ activity of Prdx6, thereby reducing the production of ROS. MJ-33 effectively inhibits the activity of acidic PLA₂ (pH 4.0), reduces the degradation of pulmonary surfactant phosphatidylcholine (PC), but has no effect on alkaline PLA₂ (pH 8.5). MJ-33 significantly alleviates lung oxidative damage induced by ischemia-reperfusion (I/R). MJ-33 significantly inhibits the invasive, migratory and adhesive abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 can be used to study ROS-related diseases and prostate cancer .
Cat. No.: HY-185008
CAS No.: 1580464-93-2
Target:
Research Areas:
CPP11G (Compound 11g) is a highly selective NADPH oxidase 2 (Nox2) inhibitor (IC50=20 μM). CPP11G is promising for research of inflammatory diseases (e.g., vasculitis, atherosclerosis) and Nox2-overactivated pathologies (e.g., ischemia-reperfusion injury) .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
